Older patients with acute myeloid leukemia (AML) have worse rates of complete remission and shorter overall survival than younger patients. The epigenetic modifier CC-486 is an oral formulation of azacitidine with promising clinical activity in patients with AML in Phase I studies. The Phase III, randomized, double-blind, placebo-controlled QUAZAR AML Maintenance trial (CC-486-AML-001) examines CC-486 maintenance therapy (300 mg/day for 14 days of 28-day treatment cycles) for patients aged ≥55 years with AML in first complete remission. The primary end point is overall survival. Secondary end points include relapse-free survival, safety, health-related quality of life and healthcare resource utilization. This trial will investigate whether CC-486 maintenance can prolong remission and improve survival for older patients with AML.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684733 | PMC |
| http://dx.doi.org/10.2217/fon.15.326 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing immunotherapy response: going beyond RECIST by integrating early tumor growth kinetics.
Front Immunol
December 2024
Median Technologies, Imaging Lab, Valbonne, France.
Objective: Assess the contribution of early tumor growth dynamics modeling to predict clinical outcomes in non-small cell lung cancer patients receiving immunotherapy, alongside standard RECIST 1.1 criteria.
Methods: Our retrospective studies used data from 861 patients with advanced NSCLC enrolled in three randomized Phase III trials evaluating immunotherapy plus chemotherapy were analyzed.
Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China.
Front Pharmacol
December 2024
Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, China.
Background: The phase III NAPOLI-3 trial, which upgraded FOLFIRINOX (leucovorin, fluorouracil, irinotecan and oxaliplatin) to NALIRIFOX (liposomal irinotecan, oxaliplatin, leucovorin, and fluorouracil), demonstrated the superiority of NALIRIFOX over GEMNABP (gemcitabine and nab-paclitaxel) as the first-line treatment for metastatic pancreatic ductal adenocarcinoma. The purpose of this study was to assess the cost-effectiveness of NALIRIFOX, FOLFIRINOX, and GEMNABP, and to simulate the price of liposomal irinotecan at which NALIRIFOX could achieve cost-effectiveness.
Methods: A partitioned survival model was performed to evaluate the cost-effectiveness of NALIRIFOX, FOLFIRINOX and GEMNABP from the perspective of the Chinese healthcare system.
Facial Emotion Recognition Ability in Individuals with Remitted Schizophrenia in Comparison to Healthy Population: A Cross-Sectional Study.
Indian J Psychol Med
January 2025
Dept. of Psychiatry, VMMC and Safdarjung Hospital, New Delhi, India.
Background: Facial emotion recognition is one of the significant domains of social cognition that underlie social interactions. These deficits can influence the functional outcome in individuals with schizophrenia by impairing judgment toward others and reducing their capability to function. We aimed to assess the facial emotion recognition deficits in individuals with schizophrenia in comparison to healthy individuals and find their association with clinical and demographic profiles.
View Article and Find Full Text PDFAccelerometers can correctly count orthopaedic patients' early post-operative steps while using walking aids.
J Exp Orthop
January 2025
Department of Orthopaedic Surgery Hannover Medical School, Laboratory for Biomechanics and Biomaterials Hannover Germany.
Purpose: Effective rehabilitation after orthopaedic surgery is critical. The early post-operative phase is increasingly managed in outpatient settings, necessitating objective measures such as step counts to monitor rehabilitation progress. However, it remains unclear if commercially available wearables or accelerometers using simple algorithms can accurately count steps in early post-operative conditions.
View Article and Find Full Text PDFAccrual Suspensions in Seamless Phase II/III Trials: A Review of NRG Oncology Trials.
JCO Oncol Adv
December 2024
Biometric Research Program, National Cancer Institute, Bethesda, MD.
Purpose: A phase II/III trial is a type of phase III trial that has embedded in it an intermediate phase II go/no-go decision as to whether to continue the accrual to the phase III sample size. We examine the design characteristics and experience of a well-defined set of National Cancer Institute phase II/III trials, with special emphasis on designed accrual suspensions while awaiting the data to become mature enough for the phase II analysis. This experience is used to highlight the potential of using a calendar backstop to avoid an inordinately long accrual suspension.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!